Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Gynecology

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 92 articles:
HTML format



Single Articles


    July 2021
  1. TJOKROWIDJAJA A, Friedlander M, Lord SJ, Asher R, et al
    Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
    Eur J Cancer. 2021;154:190-200.
    PubMed     Abstract available


    June 2021
  2. FURLANETTO J, Marme F, Seiler S, Thode C, et al
    Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
    Eur J Cancer. 2021;152:193-203.
    PubMed     Abstract available


  3. BERGAMINI A, Sarwar N, Ferrandina G, Scarfone G, et al
    Response to the Letter to the Editor by Lockley et al. commenting on 'Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis'.
    Eur J Cancer. 2021 Jun 7. pii: S0959-8049(21)00284.
    PubMed    


  4. LOCKLEY M, Stoneham S, Shamash J, Pashankar F, et al
    Re: 'Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis'.
    Eur J Cancer. 2021 Jun 4. pii: S0959-8049(21)00283.
    PubMed    


    May 2021
  5. KIM HJ, Noh WC, Nam SJ, Park BW, et al
    Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report.
    Eur J Cancer. 2021;151:190-200.
    PubMed     Abstract available


  6. WENZEL HHB, Bekkers RLM, Lemmens VEPP, Van der Aa MA, et al
    No improvement in survival of older women with cervical cancer-A nationwide study.
    Eur J Cancer. 2021;151:159-167.
    PubMed     Abstract available


    April 2021
  7. SOUKUPOVA J, Zemankova P, Nehasil P, Kleibl Z, et al
    Letter to the Editor: Comments on ERCC3 as a new ovarian cancer susceptibility gene.
    Eur J Cancer. 2021 Apr 21. pii: S0959-8049(21)00181.
    PubMed    


  8. STRADELLA A, Del Valle J, Brunet J, Lazaro C, et al
    Response to letter re: ERCC3 a new ovarian cancer susceptibility gene.
    Eur J Cancer. 2021 Apr 19. pii: S0959-8049(21)00182.
    PubMed    


    March 2021
  9. MATHEVET P, Lecuru F, Uzan C, Boutitie F, et al
    Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2).
    Eur J Cancer. 2021;148:307-315.
    PubMed     Abstract available


  10. FRANCIS KE, Gebski V, Lord SJ, Friedlander M, et al
    Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event repor
    Eur J Cancer. 2021;148:251-259.
    PubMed     Abstract available


  11. SEPPALA TT, Dominguez-Valentin M, Crosbie EJ, Engel C, et al
    Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.
    Eur J Cancer. 2021;148:124-133.
    PubMed     Abstract available


  12. MATSUO K, Shimada M, Matsuzaki S, Enomoto T, et al
    Wait-time for adjuvant radiotherapy and oncologic outcome in early-stage cervical cancer: A treatment implication during the coronavirus pandemic.
    Eur J Cancer. 2021;148:117-120.
    PubMed    


  13. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Corrigendum to "Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study [Eur J Canc 144 (2021) 341-350].
    Eur J Cancer. 2021 Mar 7. pii: S0959-8049(21)00071.
    PubMed    


    January 2021
  14. FALCONER H, Yin L, Salehi S, Altman D, et al
    Association between pelvic inflammatory disease and subsequent salpingectomy on the risk for ovarian cancer.
    Eur J Cancer. 2021;145:38-43.
    PubMed     Abstract available


  15. ROBERTSON JFR, Paridaens RJ, Lichfield J, Bradbury I, et al
    Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Eur J Cancer. 2021;145:19-28.
    PubMed     Abstract available


    December 2020
  16. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
    Eur J Cancer. 2020;144:341-350.
    PubMed     Abstract available


  17. FERRANDINA G, Aristei C, Biondetti PR, Cananzi FCM, et al
    Corrigendum to "Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)" [Eur J Canc. vol. 139 November (2020) Pages 149-168].
    Eur J Cancer. 2020 Dec 19. pii: S0959-8049(20)31301.
    PubMed    


  18. DITTO A, Casarin J, Pinelli C, Perrone AM, et al
    Corrigendum to "Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group" [European Journa
    Eur J Cancer. 2020 Dec 17. pii: S0959-8049(20)31355.
    PubMed    


  19. CIBULA D, Dostalek L, Hillemanns P, Scambia G, et al
    Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study.
    Eur J Cancer. 2020;143:88-100.
    PubMed     Abstract available


    November 2020
  20. DAFNI U, Martin-Lluesma S, Balint K, Tsourti Z, et al
    Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    Eur J Cancer. 2020;142:63-82.
    PubMed     Abstract available


  21. RESTAINO S, Tortorella L, Dinoi G, Zannoni GF, et al
    Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications.
    Eur J Cancer. 2020;142:29-37.
    PubMed     Abstract available


  22. KANG S, Yu YL, Cho SY, Park SY, et al
    Prevalence of pathogenic variants in actionable genes in advanced ovarian cancer: a next-generation sequencing analysis of a nationwide registry study.
    Eur J Cancer. 2020;141:185-192.
    PubMed     Abstract available


  23. MATSUO K, Wright JD, Matsuzaki S, Roman LD, et al
    Malignant peritoneal cytology in endometrial cancer: Areas of unmet need for evidence.
    Eur J Cancer. 2020;140:149-150.
    PubMed    


    October 2020
  24. STRADELLA A, Del Valle J, Rofes P, Vargas-Parra G, et al
    ERCC3, a new ovarian cancer susceptibility gene?
    Eur J Cancer. 2020;141:1-8.
    PubMed     Abstract available


  25. DITTO A, Casarin I, Perrone AM, Scollo P, et al
    Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group.
    Eur J Cancer. 2020;140:1-10.
    PubMed     Abstract available


    September 2020
  26. MATSUO K, Huang Y, Matsuzaki S, Klar M, et al
    Effect of delay in surgical therapy for early-stage cervical cancer: An implication in the coronavirus pandemic.
    Eur J Cancer. 2020;139:173-176.
    PubMed    


  27. FERRANDINA G, Cynthia A, Raimondo BP, Maria CFC, et al
    Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia).
    Eur J Cancer. 2020;139:149-168.
    PubMed     Abstract available


  28. BISCH S, Nelson G
    Randomised controlled trial confirms benefit of enhanced recovery after surgery on length of stay in ovarian cancer: How low can we go?
    Eur J Cancer. 2020;139:90-91.
    PubMed    


  29. TJOKROWIDJAJA A, Lee CK, Friedlander M, Gebski V, et al
    Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
    Eur J Cancer. 2020;139:59-67.
    PubMed     Abstract available


  30. PINELLI C, Bogani G, Casarin J, Raspagliesi F, et al
    Malignant peritoneal cytology in endometrial cancer.
    Eur J Cancer. 2020 Sep 10. pii: S0959-8049(20)30449.
    PubMed    


    August 2020
  31. VANDENBROUCKE T, Verheecke M, van Gerwen M, Van Calsteren K, et al
    Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy.
    Eur J Cancer. 2020;138:57-67.
    PubMed     Abstract available


  32. JANSEN EEL, Zielonke N, Gini A, Anttila A, et al
    Response to the letter commenting on 'Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review'.
    Eur J Cancer. 2020 Aug 15. pii: S0959-8049(20)30395.
    PubMed    


  33. BERGAMINI A, Sarwar N, Ferrandina G, Scarfone G, et al
    Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis.
    Eur J Cancer. 2020;137:136-143.
    PubMed     Abstract available


  34. CIBULA D, Kocian R, Plaikner A, Jarkovsky J, et al
    Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial.
    Eur J Cancer. 2020;137:69-80.
    PubMed     Abstract available


    July 2020
  35. KITSON SJ, Bafligil C, Ryan NAJ, Lalloo F, et al
    BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
    Eur J Cancer. 2020;136:169-175.
    PubMed     Abstract available


  36. SANCHEZ-IGLESIAS JL, Carbonell-Socias M, Perez-Benavente MA, Monreal Clua S, et al
    PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.
    Eur J Cancer. 2020;136:149-158.
    PubMed     Abstract available


  37. SAMUEL E, Chiang C, Jennens R, Faulkner D, et al
    Response to letter commenting on: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
    Eur J Cancer. 2020 Jul 14. pii: S0959-8049(20)30339.
    PubMed    


  38. HOWELL SJ, Keevil B, Higham C, Owen LJ, et al
    RE: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
    Eur J Cancer. 2020 Jul 11. pii: S0959-8049(20)30338.
    PubMed    


    June 2020
  39. MASTELIC-GAVILLET B, Sarivalasis A, Lozano LE, Wyss T, et al
    Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
    Eur J Cancer. 2020;135:173-182.
    PubMed     Abstract available


  40. DUGUE PA, Lynge E, Rebolj M
    Comment on 'Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review'.
    Eur J Cancer. 2020 Jun 12. pii: S0959-8049(20)30236.
    PubMed    


    May 2020
  41. VAN WEELDEN WJ, Reijnen C, Eggink FA, Boll D, et al
    Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
    Eur J Cancer. 2020;133:104-111.
    PubMed     Abstract available


  42. CHOI MC, Chung YS, Lee JW, Kwon BS, et al
    Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
    Eur J Cancer. 2020;133:56-65.
    PubMed     Abstract available


  43. MATSUO K, Matsuzaki S, Nusbaum DJ, Machida H, et al
    Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer.
    Eur J Cancer. 2020;133:33-46.
    PubMed     Abstract available


  44. WENZEL HHB, Smolders RGV, Beltman JJ, Lambrechts S, et al
    Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review.
    Eur J Cancer. 2020;133:14-21.
    PubMed     Abstract available


    April 2020
  45. LOK C, van Trommel N, Massuger L, Golfier F, et al
    Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease.
    Eur J Cancer. 2020;130:228-240.
    PubMed     Abstract available


    March 2020
  46. BERNEY DM, Shamash J, Stoneham S, Lockley M, et al
    Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2020 Mar 18. pii: S0959-8049(20)30048.
    PubMed    


  47. ONDA T, Satoh T, Ogawa G, Saito T, et al
    Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.
    Eur J Cancer. 2020;130:114-125.
    PubMed     Abstract available


  48. PASHANKAR F, Frazier AL
    Re: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2020 Mar 13. pii: S0959-8049(20)30047.
    PubMed    


  49. CRISCITIELLO C, Curigliano G
    Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours.
    Eur J Cancer. 2020;127:236-239.
    PubMed    


  50. GILBERT A, Drinkwater K, McParland L, Adams R, et al
    UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes.
    Eur J Cancer. 2020;128:7-16.
    PubMed     Abstract available


    February 2020
  51. JENSEN PT, Schnack TH, Froding LP, Bjorn SF, et al
    Survival after a nationwide adoption of robotic minimally invasive surgery for early-stage cervical cancer - A population-based study.
    Eur J Cancer. 2020;128:47-56.
    PubMed     Abstract available


    January 2020
  52. JANSEN EEL, Zielonke N, Gini A, Anttila A, et al
    Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review.
    Eur J Cancer. 2020 Jan 21. pii: S0959-8049(19)30868.
    PubMed     Abstract available


  53. BAGRATUNI T, Mavrianou N, Gavalas NG, Tzannis K, et al
    JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
    Eur J Cancer. 2020;126:125-135.
    PubMed     Abstract available


  54. SAMUEL E, Chiang C, Jennens R, Faulkner D, et al
    Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
    Eur J Cancer. 2020;126:104-105.
    PubMed    


  55. WOJTYLA C, Janik-Koncewicz K, La Vecchia C
    Cervical cancer mortality in young adult European women.
    Eur J Cancer. 2020;126:56-64.
    PubMed     Abstract available


    December 2019
  56. RUSAN M, Andersen RF, Jakobsen A, Steffensen KD, et al
    Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
    Eur J Cancer. 2019;125:121-129.
    PubMed     Abstract available


    November 2019
  57. FLAUM N, Crosbie EJ, Woodward ER, Lalloo F, et al
    Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants.
    Eur J Cancer. 2019;124:88-90.
    PubMed    


  58. LOOPIK DL, IntHout J, Melchers WJG, Massuger LFAG, et al
    Oral contraceptive and intrauterine device use and the risk of cervical intraepithelial neoplasia grade III or worse: a population-based study.
    Eur J Cancer. 2019;124:102-109.
    PubMed     Abstract available


    September 2019
  59. CHOI MC, Oh J, Lee C
    Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia.
    Eur J Cancer. 2019;121:94-97.
    PubMed    


    July 2019
  60. VAN DER HEL OL, Timmermans M, van Altena AM, Kruitwagen RFPM, et al
    Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989-2015.
    Eur J Cancer. 2019;118:97-104.
    PubMed     Abstract available


  61. DEPANI S, Stoneham S, Krailo M, Xia C, et al
    Results from the UK Children's Cancer and Leukaemia Group study of extracranial germ cell tumours in children and adolescents (GCIII).
    Eur J Cancer. 2019;118:49-57.
    PubMed     Abstract available


  62. LEE CK, Asher R, Friedlander M, Gebski V, et al
    Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.
    Eur J Cancer. 2019;117:99-106.
    PubMed     Abstract available


    June 2019
  63. ALFONZO E, Wallin E, Ekdahl L, Staf C, et al
    No survival difference between robotic and open radical hysterectomy for women with early-stage cervical cancer: results from a nationwide population-based cohort study.
    Eur J Cancer. 2019;116:169-177.
    PubMed     Abstract available


  64. PERSSON J, Salehi S, Bollino M, Lonnerfors C, et al
    Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging.
    Eur J Cancer. 2019;116:77-85.
    PubMed     Abstract available


  65. ROUSSET-JABLONSKI C, Selle F, Adda-Herzog E, Planchamp F, et al
    Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers.
    Eur J Cancer. 2019;116:35-44.
    PubMed     Abstract available


  66. PERRONE F, De Laurentiis M, De Placido S, Orditura M, et al
    Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
    Eur J Cancer. 2019 Jun 1. pii: S0959-8049(19)30297.
    PubMed     Abstract available


    May 2019
  67. FROEHLICH K, Schmidt A, Heger JI, Al-Kawlani B, et al
    Breast cancer, placenta and pregnancy.
    Eur J Cancer. 2019;115:68-78.
    PubMed     Abstract available


    April 2019
  68. NEWTON C, Murali K, Ahmad A, Hockings H, et al
    A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2019;113:19-27.
    PubMed     Abstract available


    February 2019
  69. DELLE MARCHETTE M, Ceppi L, Andreano A, Bonazzi CM, et al
    Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery.
    Eur J Cancer. 2019;111:61-68.
    PubMed     Abstract available


  70. ANDERSSON TM, Engholm G, Lund AQ, Lourenco S, et al
    Avoidable cancers in the Nordic countries-the potential impact of increased physical activity on postmenopausal breast, colon and endometrial cancer.
    Eur J Cancer. 2019;110:42-48.
    PubMed     Abstract available


  71. FRIJSTEIN MM, Lok CAR, Short D, Singh K, et al
    The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia.
    Eur J Cancer. 2019;109:162-171.
    PubMed     Abstract available


    January 2019
  72. JORGENSEN SL, Mogensen O, Wu CS, Korsholm M, et al
    Survival after a nationwide introduction of robotic surgery in women with early-stage endometrial cancer: a population-based prospective cohort study.
    Eur J Cancer. 2019;109:1-11.
    PubMed     Abstract available


    November 2018
  73. MENZER C, Beedgen B, Rom J, Duffert CM, et al
    Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy.
    Eur J Cancer. 2018;104:239-242.
    PubMed    


    September 2018
  74. CAMPONE M, Im SA, Iwata H, Clemons M, et al
    Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
    Eur J Cancer. 2018;103:147-154.
    PubMed     Abstract available


    July 2018
  75. BOUVARD B, Chatelais J, Soulie P, Hoppe E, et al
    Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
    Eur J Cancer. 2018;101:87-94.
    PubMed     Abstract available


  76. BRETTHAUER M, Goderstad JM, Loberg M, Emilsson L, et al
    Uterine morcellation and survival in uterine sarcomas.
    Eur J Cancer. 2018;101:62-68.
    PubMed     Abstract available


  77. HESCOT S, Haissaguerre M, Pautier P, Kuhn E, et al
    Immunotherapy-induced Addison's disease: A rare, persistent and potentially lethal side-effect.
    Eur J Cancer. 2018;97:57-58.
    PubMed    


    June 2018
  78. MEYS EMJ, Jeelof LS, Ramaekers BLT, Dirksen CD, et al
    Economic evaluation of an expert examiner and different ultrasound models in the diagnosis of ovarian cancer.
    Eur J Cancer. 2018;100:55-64.
    PubMed     Abstract available


    May 2018
  79. FRAZIER AL, Stoneham S, Rodriguez-Galindo C, Dang H, et al
    Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium.
    Eur J Cancer. 2018;98:30-37.
    PubMed     Abstract available


  80. MANDALA M, Merelli B, Indriolo A, Tondini C, et al
    Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.
    Eur J Cancer. 2018;95:130-132.
    PubMed    


    April 2018
  81. NABIEVA N, Fehm T, Haberle L, de Waal J, et al
    Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
    Eur J Cancer. 2018;96:82-90.
    PubMed     Abstract available


  82. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
    Eur J Cancer. 2018;95:59-67.
    PubMed     Abstract available


  83. PLOQUIN A, Pistilli B, Tresch E, Frenel JS, et al
    5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.
    Eur J Cancer. 2018;95:30-37.
    PubMed     Abstract available


  84. MOKE DJ, Thomas SM, Hiemenz MC, Nael A, et al
    Three synchronous malignancies in a patient with DICER1 syndrome.
    Eur J Cancer. 2018;93:140-143.
    PubMed    


    January 2018
  85. PEDERSEN K, Burger EA, Nygard M, Kristiansen IS, et al
    Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Eur J Cancer. 2018;91:68-75.
    PubMed     Abstract available


  86. DUHIL DE BENAZE G, Pacquement H, Faure-Conter C, Patte C, et al
    Paediatric dysgerminoma: Results of three consecutive French germ cell tumours clinical studies (TGM-85/90/95) with late effects study.
    Eur J Cancer. 2018;91:30-37.
    PubMed     Abstract available


    November 2017
  87. TIMMERMANS M, Sonke GS, Van de Vijver KK, van der Aa MA, et al
    No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands.
    Eur J Cancer. 2017;88:31-37.
    PubMed     Abstract available


  88. TEMKIN SM, Miller EA, Samimi G, Berg CD, et al
    Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.
    Eur J Cancer. 2017;87:182-188.
    PubMed     Abstract available


  89. ANDERSON RA, Mansi J, Coleman RE, Adamson DJA, et al
    The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Eur J Cancer. 2017;87:58-64.
    PubMed     Abstract available


    October 2017
  90. VERSLUIS MAC, Marchal S, Plat A, de Bock GH, et al
    The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment.
    Eur J Cancer. 2017;86:285-295.
    PubMed     Abstract available


  91. VERMEULEN RFM, Beurden MV, Kieffer JM, Bleiker EMA, et al
    Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
    Eur J Cancer. 2017;84:159-167.
    PubMed     Abstract available


    September 2017
  92. VANDERSTICHELE A, Busschaert P, Olbrecht S, Lambrechts D, et al
    Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    Eur J Cancer. 2017;86:5-14.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: